LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood

Forensic Science International

Volumn 229, Issue 1-3, 2013, Pages 145-150

  Fisher, Danielle S ^a   Partridge, Suzanne J ^a   Handley, Simon A ^a   Couchman, Lewis ^a   Morgan, Phillip E ^a   Flanagan, Robert J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical antipsychotics; Haemolysed whole blood; LC MS MS; Oral fluid; Sulpiride; TDM

Indexed keywords

AMISULPRIDE; AMMONIUM ACETATE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTANOL; CLOZAPINE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; LY 170222; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; AUTOPSY; BLOOD ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION KINETICS; DILUTION; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; FLOW RATE; HEMOLYSIS; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PH; PRIORITY JOURNAL; REPRODUCIBILITY; SALIVA ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 84885953518     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2013.02.010     Document Type: Article

References (20)

1. C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier, K. Egberts, M. Fric, M. Gerlach, C. Greiner, G. Gründer, E. Haen, U. Havemann-Reinecke, E. Jaquenoud Sirot, H. Kirchherr, G. Laux, U.C. Lutz, T. Messer, M.J. Müller, B. Pfuhlmann, B. Rambeck, P. Riederer, B. Schoppek, J. Stingl, M. Uhr, S. Ulrich, R. Waschgler, G. Zernig, AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011, Pharmacopsychiatry 44 (2011) 195-235.
2. D.S. Fisher, G.I. van Schalkwyk, S. Seedat, S.R. Curran, R.J. Flanagan, Plasma, oral fluid, and whole-blood distribution of antipsychotics and metabolites in clinical samples, Ther. Drug Monit. (2013), ahead of print.
3. P.N. Patsalos, D.J. Berry, Therapeutic drug monitoring of antiepileptic drugs by use of saliva, Ther. Drug Monit. 35 (2013) 4-29.
4. W.W. Zhao, E. Jacqz-Aigrain, Principles of therapeutic drug monitoring, Handb. Exp. Pharmacol. 205 (2011) 77-90.
5. R. Uřinovská, H. Brozmanová, P. Sištík, P. Silhán, I. Kacířová, K. Lemr, M. Grundmann, Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 907 (2012) 101-107.
6. K. Titier, S. Bouchet, F. Péhourcq, N. Moore, M. Molimard, High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 788 (2003) 179-185.
7. J. Sachse, J. Köller, S. Härtter, C. Hiemke, Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830 (2006) 342-348.
8. D. Remane, M.R. Meyer, D.K. Wissenbach, H.H. Maurer, Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs, Anal. Bioanal. Chem. 401 (2011) 1341-1352.
9. D.S. Patel, N. Sharma, M.C. Patel, B.N. Patel, P.S. Shrivastav, M. Sanyal, LC-MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study, Acta Pharmaceut. Sinic. B 2 (2012) 481-494.
10. E. Saar, J. Beyer, D. Gerostamoulos, O.H. Drummer, The analysis of antipsychotic drugs in human matrices using LC-MS(/MS), Drug Test. Anal. 4 (2012) 376-394.
11. K. Madej, A. Biedron, A. Garbacik, Study of separation and extraction conditions for five neuroleptic drugs by an LLE-HPLC-DAD method in human plasma, J. Liq. Chromatogr. R. T. 32 (2009) 3025-3037.
12. FDA/CDER, Guidance for industry: bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf, 2001 (accessed 18.07.11).
13. D. Tholen, A. Kallner, J. Kennedy, J.S. Krouwer, K. Meier, Evaluation of precision performance of quantitative measurement methods; Approved Guideline-Second Edition. Available at: http://webstore.ansi.org/ansidocstore/product.asp?sku=EP05%2DA2, 2004 (accessed 10.07.12).
14. R. Bonfiglio, R.C. King, T.V. Olah, K. Merkle, The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds, Rapid Commun. Mass Spectrom. 13 (1999) 1175-1185.
15. D.S. Fisher, S.J. Partridge, S.A. Handley, R.J. Flanagan, Stability of some atypical antipsychotics in human plasma, human serum, calf serum, oral fluid and haemolysed whole blood, submitted for publication.
16. D.S. Fisher, S.A. Handley, D. Taylor, R.J. Flanagan, Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS, Biomed. Chromatogr. 26 (2012) 1125-1132.
17. R.J. Flanagan, Therapeutic monitoring of antipsychotic drugs, Internat. Labmate. 33 (2008) 6-7.
18. E. Saar, D. Gerostamoulos, O.H. Drummer, J. Beyer, Identification and quantification of 30 antipsychotics in blood using LC-MS/MS, J. Mass Spectrom. 45 (2010) 915-925.
19. C. Kratzsch, F.T. Peters, T. Kraemer, A.A. Weber, H.H. Maurer, Screening, libraryassisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization, J. Mass Spectrom. 38 (2003) 283-295.
20. R.J. Flanagan, B. Yusufi, T.R. Barnes, Comparability of whole-blood and plasma clozapine and norclozapine concentrations, Br. J. Clin. Pharmacol. 56 (2003) 135-138.